Yolaine J. Jeune-Smith, PhD

Research Reports

Community Oncologists‚ Perception and Adaptability to Emerging Chimeric Antigen T-Cell Therapy

10/16/2017

Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...

...

10/16/2017

Journal of Clinical Pathways

Research Reports

The Role and Scope of Practice of Advanced Practice Providers in United States Community Oncology

04/21/2020

Ajeet Gajra , MD, FACP;

Ting-Chun Yeh , PhD;

Chadi Nabhan , MD, MBA, FACP;

Yolaine J. Jeune-Smith , PhD;

Bruce A. Feinberg , DO;

Andrew J. Klink , PhD, MPH;

Bela Bapat , MS;

Abstract: In the era of value-based care and constrained resources, oncology practices are increasingly employing advanced practice providers (APPs) to improve practice workflow, increase efficiency, and enable...

...

04/21/2020

Journal of Clinical Pathways

From the Field

Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists

10/20/2021

Skyler Hime Rupard , MS;

Ajeet Gajra , MD, FACP;

Yolaine J. Jeune-Smith , PhD;

Bruce A. Feinberg , DO;

Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer

Ajeet Gajra, MD, FACP, et al...

10/20/2021

Journal of Clinical Pathways

Research Reports

Community Oncologists` Perception and Acceptance of Biosimilars in Oncology

09/13/2018

Yolaine J. Jeune-Smith , PhD;

Amy Valley , PharmD;

Bruce A. Feinberg , DO;

Chadi Nabhan , MD, MBA, FACP;

Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...

...

09/13/2018

Journal of Clinical Pathways